Higher Risk, Lowered Age: New Colorectal Cancer Screening Guidelines
Host: John J. Russell, MD Guest: Richard Wender, MD From oncologists to primary care, physicians are witnessing an alarming trend in younger patients:...
Focus on Cancer
Share:
Listens: 16
About
According to the American Cancer Society, yearly deaths from cancer are decreasing— marking the first period of decline in nearly 70 years. ReachMD takes a closer look at the driving forces behind these advances: medications that hone in on specific tumor targets, more accurate screening and diagnostic technologies, and pioneering surgical methods that provide new hope for patients suffering from these devastating diseases.
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosi...
CAR-T Cell Therapy: A Breakthrough Treatment for Fighting Cancer
Host: Shira Johnson, MD Guest: Robert Vonderheide, MD For years, the foundations of cancer treatment, surgery, chemotherapy, and radiation therapy wer...
Pancreatic Cancer: The Hunt to Catch a Silent Killer
Host: John J. Russell, MD Guest: Harish Lavu, MD Pancreatic cancer is projected to become the second leading cause of cancer-related death in the Unit...
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. Released July 28, 2017
FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer
FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer. Released July 25, 2017
The CAM Guide to Cancer: An Integrative Approach to Prevention, Treatment, and Healing
Host: Kathy King, RDN Guest: Lise Alschuler, ND Host Kathy King sits down with Dr. Lise Alschuler, naturopathic doctor, cancer survivor, and author of...
Linking p53 Variation to Breast Cancer Risk in African American Women
Host: Brian P. McDonough, MD, FAAFP It's widely known that genetics, family history, race, and other factors all play important roles in cancer risk. ...
FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval
The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in ...
The Financial Burden of Cancer: Report from the American Cancer Society
Host: Brian P. McDonough, MD, FAAFP Host Dr. Brian McDonough chats with Jennifer Singleterry, Senior Analyst of Policy and Legislative Support for the...